Form 4: X4 Pharmaceuticals Director David McGirr Granted 1,500 Restricted Stock Units

X4 Pharmaceuticals, Inc. Director David W.J. McGirr was granted 1,500 restricted stock units (RSUs) as an annual award for his board service, increasing his direct beneficial ownership to 4,722 shares.

Summary

• David W.J. McGirr, a Director of X4 Pharmaceuticals, Inc. (XFOR), acquired 1,500 shares of Common Stock on June 9, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) as an annual award for his service on the Board of Directors, with a transaction price of $0 per unit.
• Following this transaction, Mr. McGirr directly beneficially owns 4,722 shares of Common Stock.
• The RSUs are set to vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, contingent on his continued board service.
• Full vesting of the RSUs will also occur upon a change in control of X4 Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders, indicating continued commitment and incentivization. However, it is a routine compensation disclosure rather than a significant operational or financial announcement that would dramatically alter the company's outlook.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• This RSU grant is a standard component of director compensation, indicating ongoing commitment and incentivization for board service.

Future Outlook

The granted Restricted Stock Units are subject to future vesting, which will occur on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders, provided continued board service. Full vesting will also occur upon a change in control of the Issuer.

Management Comments

• The filing was signed by Adam S. Mostafa, attorney-in-fact for David W.J. McGirr.

Industry Context

The grant of restricted stock units to board members is a common and widely accepted practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors as part of their annual compensation is a standard practice across publicly traded companies, particularly within the biotech and pharmaceutical sectors, including peers like BioNTech SE, Moderna, Inc., and Gilead Sciences, Inc., which frequently utilize equity awards to incentivize and retain board members.
• The vesting schedule, tied to continued service or a change in control, is typical for such awards, ensuring alignment with long-term company performance and strategic events.

Corporate Governance

Related Party Transactions

• The acquisition of 1,500 Restricted Stock Units by Director David W.J. McGirr from X4 Pharmaceuticals, Inc. is a related party transaction, representing a form of compensation for his board service.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units will vest on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders, subject to continued board service.
• The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

Key Dates

Keywords

X4 Pharmaceuticals, XFOR, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Corporate Governance